Roche has signed an agreement to acquire Poseida Therapeutics in a $1.5bn deal. The transaction includes Poseida's clinical and pre-clinical CAR-T therapies and manufacturing capabilities.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market. Learn more on RHHBY stock here.

Shares of Poseida Therapeutics Inc. ($PSTX) surged over 200% on Tuesday, reaching levels not seen since August 2021, after the company announced its acquisition by ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical company specializing in complex immune cell therapies to treat several ...

ZURICH, Jan 8 (Reuters) - Roche (ROG.S), opens new tab on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics (PSTX.O), opens new tab ...

Two years after partnering with Poseida Therapeutics on off-the-shelf CAR-T therapeutics, Roche has decided it wants to take full control of the company and its technology platforms. The Swiss ...

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...

Poseida Therapeutics, Inc. (NASDAQ:PSTX), a biotechnology company specializing in biological products with a market capitalization of $929 million, announced today that it has completed a ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

Poseida Therapeutics has completed a merger where it has become a wholly owned subsidiary of a Parent company. As a result of the merger, the company has delisted its shares from Nasdaq and plans ...